Silodosin

SKU: orb1308412

Description

Silodosin

Research Area

Infectious Disease & Virology, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 160970-54-7
• MW: 495.53
• Purity: 99.76% (May vary between batches)
• Formula: C₂₅H₃₂F₃N₃O₄
• SMILES: C(CCO)N1C=2C(=CC(C[C@H](NCCOC3=C(OCC(F)(F)F)C=CC=C3)C)=CC2C(N)=O)CC1
• Target: Antibacterial,Adrenergic Receptor
• Solubility: DMSO:92 mg/mL (185.66 mM);Ethanol:92 mg/mL (185.66 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.66 mM)

Bioactivity

• Target IC50:
  α1D-adrenoceptor:2 nM (Ki)|α1B-adrenoceptor:21 nM (Ki)|α1A-adrenoceptor:0.036 nM (Ki)
• In Vivo:
  Silodosin and tadalafil synergistically inhibit neurally-mediated contraction effects in human and rat ex vivo prostates. Compared to tamsulosin hydrochloride, naftopidil, or prazosin hydrochloride, Silodosin exhibits higher selectivity for the α(1A)-AR subtype, with the affinity order being highest for tamsulosin hydrochloride, followed by Silodosin, prazosin hydrochloride, or naftopidil.
  Read more...
• In Vitro:
  Silodosin (0.1-0.3 mg/kg) significantly reduces intralumenal ureteral pressure by 21-37% in obstruction-induced scenarios, whereas Phentolamine (0.03-0.1 mg/kg) can increase it by 18-40%. In dogs with benign prostatic hyperplasia, Silodosin (0.3-300 mg/kg) dose-dependently inhibits the increase in urethral pressure induced by pelvic nerve stimulation without notable hypotensive effects. In rabbit lower urinary tract tissues, Silodosin markedly antagonizes contractions induced by norepinephrine (including in the prostate, urethra, and bladder trigone, with PA(2) or pKb values of 9.60, 8.71, and 9.35, respectively). Oral administration of Silodosin in rats significantly inhibits the increase in urethral pressure caused by phenylephrine at 12 h, 18 h, and 24 h post-administration compared to the control group. Silodosin exhibits inhibitory effects on isolated contractions of rat and human ureters and possesses strong functional selectivity for relieving pressure in ureteral obstruction in rats.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

prostatic, tract, symptoms, Silodosin, β-adrenergic receptor, urinary, BPH, cancer, Adrenergic Receptor, AdrenergicReceptor, Beta Receptor, benign, lower, LUTS, inhibit, KAD 3213, KAD3213, KAD-3213, KMD 3213, KMD3213, KMD-3213, Inhibitor, hyperplasia

Compound Identifiers

PubChem CID

5312125